AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

HAEMONETICS CORP Director's Dealing 2018

Nov 9, 2018

31565_dirs_2018-11-09_23d46e70-b79a-4f67-9bf8-6b2f383616c1.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: HAEMONETICS CORP (HAE)
CIK: 0000313143
Period of Report: 2018-11-08

Reporting Person: Burke William P. Mr. (EVP, Chief Financial Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2018-11-08	Common Stock	M	11232	$34.21	Acquired	25057	Direct
2018-11-08	Common Stock	S	13056	$114.33	Disposed	12001	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2018-11-08	Non-qualified Stock Option (Right to Buy)	$34.21	M	11232	Disposed	2023-10-25	Common Stock (11232)	Direct

Footnotes

F1: Transaction pursuant to an existing 10b5-1 trading plan.

F2: This number includes unvested restricted stock units previously reported.

F3: Grant to reporting person of right to buy shares of common stock exercisable in annual increments of 25 percent beginning on the first anniversary of the date of grant.